← Eichor
Study identifier: NCT06831071 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of Hypoxia in Primary Melanoma

Condition: Melanoma  ·  Sponsor: Yana Najjar

PhaseN/A
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

When controlling for tumor present in the Sentinel lymph node (SLN), intranodal hypoxia, as measured by Carbonic Anhydrase IX (CAIX IHC), is associated with worse PFS. This suggests that melanoma tumors may be utilizing deregulated metabolism as a means of propagating themselves to the next station of metastasis. This study aims to prospectively validate previous findings. Patients who are to undergo WLE and SLNB per standard of care (SOC) will be evaluable. It is hypothesized that SLN(s) with increased hypoxia, as measured by pimonidazole staining, will be associated with worse Progression-free Survival (PFS).

This description comes directly from the study's public registry record.

Talk to the study team

Danielle L Bednarz, RN, BSN  ·  4126231191  ·  bednarzdl@upmc.edu

Amy Rose, RN, BSN  ·  412-647-8587  ·  kennaj@upmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UPMC Hillman Cancer CenterPittsburgh, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06831071